Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoChange DetectedNew user guidance sections and a recruitment status update were added to the study page, clarifying participation options and how to navigate the record. A formatting tweak to the Intervention/Treatment heading and the revision label were updated.SummaryDifference0.4%

- Check10 days agoChange DetectedThe page revision was updated to v3.5.5, indicating an internal update to the page rendering or content management system.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedAdded update dates 2026-05-20, 2026-05-05, and 2026-05. Removed 2025-11-18, 2025-11-05, and 2025-11, reflecting changes to the page's revision history.SummaryDifference0.2%

- Check32 days agoChange DetectedAdded the page revision tag v3.5.4 to replace the previous v3.5.3, indicating the page was updated. This update appears to reflect a revision history change rather than content changes to the study details.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page’s displayed revision number has been updated from v3.5.0 to v3.5.3.SummaryDifference0.0%

- Check89 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.